



HFS

Illinois Department of
Healthcare and Family Services

JB Pritzker, Governor

201 South Grand Avenue East, Springfield, Illinois 62763

Theresa A. Eagleson, Director

Telephone: +1 217-782-1200, TTY: +1 800-526-5812

**Illinois Drug Utilization Review
Board Meeting Minutes
July 27, 2023**

I. Call to Order, Roll Call

- a. Call to order
 - i. Meeting conducted via a Webex webinar format.
 - ii. The meeting was recorded in accordance with the Open Meetings Act. Guests wishing to speak during public comment were requested to type name and affiliation in the Webex Chat.
 - iii. Dr. Schriever called the meeting to order at 8:31am. Motion to call meeting to order made by Dr. An, seconded by Dr. Nikocecic.
 - iv. Vote: In favor- 4; Against- 0; Abstentions- 0. Meeting commenced.
- b. Roll call
 - i. Roll call was taken, and a quorum was established. Present: Drs. Schriever, An, Nikocecic, Stevens. Not present: Drs. Ahluwalia, Sreedhar

II. Agenda, conflict of interest review, and approval of April 27, 2023 meeting minutes

- a. No DUR Board members had conflicts of interest pertinent to the agenda. Dr. Schriever reminded DUR Board members to recuse themselves from discussion if conflicts of interest are present and to provide an updated *Conflict of Interest* form if new conflicts arise.
- b. April 27, 2023 meeting minutes- No changes or additions. Motion to approve made by Dr. An, seconded by Dr. Stevens.
- c. Vote: In favor- 4; Against- 0; Abstentions- 0. April 27, 2023 meeting minutes approved.

III. Quarterly Reports – presented by Maurice Shaw, PharmD

- a. Top 10 spend Fee-For-Service (FFS) drugs (2023Q2)
- b. Top 10 script count FFS- Prescription only (2023Q2)
- c. Top 10 script count FFS- OTC only (2023Q2)
- d. Top 5 script count by disease state: Diabetes (FFS and Managed Care Organization (MCO), 2023Q1)
 - i. Board suggested Dr. Shaw investigate glipizide prescribing.
- e. Top 5 script count by disease state: Hypertension (FFS and MCO, 2023Q1)
- f. Top 5 script count by disease state: Depression (FFS and MCO, 2023Q1)
- g. Top 5 script count by disease state: Asthma (FFS and MCO, 2023Q1)
- h. Prior authorization approvals and denials (2023Q2)
 - i. Percentages are similar to those presented for 2023Q1 at the April meeting.
- i. Clinical denial reasons (2023Q2)

IV. RetroDUR 300 – presented by Christina Petrykiw, PharmD, CDCES

- a. RetroDUR 300
 - i. As of July 2023, 126 patients- FFS, 174 patients MCO, Medicare, or third-party insurance, no HFS coverage, or deceased
 - ii. Prescriber outreach ongoing concerning subtherapeutic dosing and duplicate therapy.
 - iii. Possible duplicate therapy edits needed: Budesonide- concurrent use of different dosage forms and strengths are currently being monitored, but no changes recommended at this time.



HFS

Illinois Department of
Healthcare and Family Services

JB Pritzker, Governor

201 South Grand Avenue East, Springfield, Illinois 62763

Theresa A. Eagleson, Director

Telephone: +1 217-782-1200, TTY: +1 800-526-5812

- b. SUPPORT Act edits
 - i. Initial script edit
 - a. For both FFY21 and FFY22, hydrocodone combination had the highest claim count.
 - b. There was a 10% decrease in the number of claims that triggered the edit from FFY21 to FFY22.
 - c. These claims counts are reflective of the initial day supply of 7 days. HFS implemented the 5-day supply update in February 2023, but it is too early to report on FFY23 claims.
 - ii. MME edit
 - a. For FFY21, oxycodone had the highest claim count. For FFY22, hydromorphone had the highest claim count.
 - b. There was an 8.8% decrease in the number of claims that triggered the edit from FFY21 to FFY22.
 - c. An increased number of claims for hydromorphone and tramadol triggered the edit between fiscal years.
- V. **Prospective DUR** – Presented by Christina Petrykiw, PharmD, CDCES
 - a. Entresto (sacubitril/valsartan) and angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB)
 - i. Implemented safety edit
 - a. ACEI and ARB: look back 90 days for Entresto
 - b. Prior authorization required for ACEI/ARB if filling Entresto
 - b. Insulin Interactions
 - i. Two patient cases presented, demonstrating claims for multiple insulin products from multiple prescribers, multiple pharmacies, and multiple long-acting insulin products prescribed by providers in the same system.
 - ii. Proposed insulin edits
 - a. One long-acting insulin at a time
 - b. One rapid short-acting insulin at a time
 - c. Rapid short-acting insulin not to be given with an intermediate (NPH) mixed insulin product
 - d. Intermediate (NPH) alone or in a mixed product, not to be given with a long-acting or ultra long-acting insulin.
 - iii. Discussion
 - a. Lookback period for the edit.
 - b. Need for a prescriber notice, patient letter, or academic detailing regarding high-alert medications.
 - c. Motion made by Dr. Stevens for HFS to research sending letters to patients on high-alert medications, seconded by Dr. An. HFS staff noted that the database is not always current for patient's contact information.
 - d. Vote: In favor- 4; Against- 0; Abstentions- 0. Motion passes.
 - e. Motion to bring proposed insulin edits to HFS Director for implementation made by Dr. Nikocecic, seconded by Dr. Stevens.
 - f. Vote: In favor- 4; Against- 0; Abstentions- 0. Motion passes.
 - c. Continuous glucose monitors (CGM)
 - i. ADA 2023 Standards of Care were reviewed.
 - ii. Medicare coverage updates effective April 2023
 - iii. Illinois legislation



HFS

Illinois Department of
Healthcare and Family Services

JB Pritzker, Governor

201 South Grand Avenue East, Springfield, Illinois 62763

Theresa A. Eagleson, Director

Telephone: +1 217-782-1200, TTY: +1 800-526-5812

- a. Public Act 102-1093, new section 215 ILCS 5/356z.53
- b. HFS Provider Notice- July 25, 2022
- iv. Current HFS criteria
 - a. Prescriber requirements
 - b. Prescriber attestation regarding patient training
 - c. Required CGM device standards
- v. Discussion
 - a. Potential modifications to the current Illinois Medicaid CGM criteria.
 - a. Remove the requirement to see/consult an endocrinologist.
 - b. Remove the intensive regimen requirement.
 - b. HFS commented the current Illinois Medicaid CGM criteria versus the new guidelines is being reviewed. Updates will be forthcoming.
 - c. Motion made by Dr. Nikocecic to remove the prescriber restriction from the Illinois Medicaid CGM criteria.
 - d. Vote: In favor- 2; Against- 2; Abstentions- 0. Motion did not pass.

VI. Public Comments

Speakers were limited to 3 minutes concerning topics on the agenda only.

- a. Gary Dougherty, Director of State Government Affairs, American Diabetes Association
- b. Garth Reynolds, Executive Director, Illinois Pharmacists Association
- c. Starlin Haydon-Greatting, Director of Clinical Programs & Population Health, Illinois Pharmacists Association
- d. Arati Reddy, MD, Endocrinologist
- e. Anila Bindal, MD, Endocrinologist
- f. Sirimon Reutrakul, MD, Endocrinologist
- g. John Keller, Clinical Pharmacist, Northwestern Medicine

VII. Updates – Presented by Jen DeWitt, BSPHarm

- a. Implementation dates pending for previously recommended RetroDUR 300 edits and smoking cessation.

VIII. Announcements – Presented by Jen DeWitt, BSPHarm

- a. Currently converting our DUR procedures to bylaws. The bylaws will be reviewed with the HFS Bureau Chief and Medical Director and then distributed to the Board for approval.
- b. Provider Notice was sent out regarding Hepatitis C medications. As of July 1, 2023, Mavyret and sofosbuvir/velpatasvir (generic Epclusa) are preferred on the Illinois Medicaid Preferred-Drug list (PDL).

IX. Future Agenda Items – Presented by Claudia Colombo, PharmD

- a. Potential topics for future review were presented, including selected measures from Healthcare Effectiveness Data & Information Set (HEDIS), CMS Medicare Stars ratings, and CMS Merit-based Payment System (MIPS), as well as a list of suggested target interventions from the US Dept. of Justice.
- b. Board expressed interest in:
 - i. Topics related to statin therapy measures and measures targeting cardiovascular disease.
 - ii. Data regarding patients receiving single-ingredient buprenorphine along with multiple controlled substances and stimulants.
 - iii. Hemophilia program process.



HFS

Illinois Department of
Healthcare and Family Services

JB Pritzker, Governor

201 South Grand Avenue East, Springfield, Illinois 62763

Theresa A. Eagleson, Director

Telephone: +1 217-782-1200, TTY: +1 800-526-5812

X. Adjournment

- a. Next DUR Board Meeting- Thursday, October 26, 2023, 8:30am – 10:30am
- b. Dr. Schriever moved to adjourn the meeting at 10:29am. Seconded by Dr. An.
- c. Vote: In favor- 4; Against- 0; Abstentions- 0. Meeting adjourned.

Meeting Attendance

DUR Board Members

Christopher Schriever, PharmD, MS, AAHVP, Chair
Sam An, PharmD
Bedrija Nikocevic, PharmD, BCACP
Erica Stevens, PharmD, BCGP

Staff/Panelists

Donna Clay, BSP Pharm – UIC
Claudia Colombo, PharmD – UIC Springfield
Jen DeWitt, BSP Pharm – UIC Springfield
Sheri Dolan, BSP Pharm – UIC Springfield
Thomas Dorn, PharmD – UIC
Heather Freeman – BPAS
Arvind Goyal, MD, MPH, MBA - Medical Director, HFS
Jose Jimenez, Bureau Chief – BPAS
Debra Long – BPAS
Christina Petrykiw, PharmD, CDCES – UIC
Maurice Shaw, PharmD – UIC Springfield

Guests/Attendees

Robert Baldrige
Stefan Beck
Anila Bindal
Matthew Bradley
Kimbra Brooks
Vermille Buchanan
John Bullard
Derek Bush
Nerissa Caballes
Stephanie Cooper
Joseph Dang
Gary Dougherty
Jeff Draper
Karen Finn
Starlin Haydon-Greatting
Steve Hiemenz
Clemice Hurst
Mark Jacobs
Manjula Jayabalan
Doug Johnson
Mary Kaneaster



HFS

**Illinois Department of
Healthcare and Family Services**

JB Pritzker, Governor

201 South Grand Avenue East, Springfield, Illinois 62763

Theresa A. Eagleson, Director

Telephone: +1 217-782-1200, TTY: +1 800-526-5812

John Keller
Jeff Knappen
Chris Lato
Phil Lohec
Gene McCarty
Debra Minard
Neelesh Nadkarni
Keith O'Hara
Nichole Palusinski
Gary Parenteau
Steve Patterson
Pawel Piechocinski
Arati Reddy
Boro Reljic
Sirimon Reutrakul
Garth Reynolds
Kenneth Ring
Ken Ryan
Christie Schumacher
Robin Selsor
Michele Shirley
Steve Sproat
Christy Vaughn
Charise Westbrooks
Chase Williams
Brian Wojcicki
Call-in User 2 (217558****)
Call-in User 4 (816830****)
Call-in User 6 (224204****)
Call-in User 7 (630903****)
Call-in User 8 (724417****)

Approved October 26, 2023 by the Illinois Drug Utilization Review Board